Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Squamous Cell / drug therapy*
  • Ear Neoplasms / drug therapy
  • Facial Neoplasms / drug therapy
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Middle Aged
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Skin Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • pembrolizumab